Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Carotid Atherosclerosis
NCT05975554Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of aldesleukin in carotid atheroma (CAS) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Difference in gene expression in Tregs. Started Aug 2023; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
carotid atheroma (CAS)
Beyond the preview
Go deeper on NCT05975554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975554.